Galectin Therapeutics (GALT) Enterprise Value (2010 - 2026)

Galectin Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$14.1 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 89.89% year-over-year to -$14.1 million in Q1 2026; TTM through Mar 2026 was -$14.1 million, a 89.89% decrease from a year earlier, with the FY2025 full-year figure at -$17.7 million, down 17.2% from the prior year.
• Enterprise Value advanced to -$14.1 million in Q1 2026 per GALT's latest filing, from -$17.7 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$7.4 million in Q1 2025 and bottomed at -$31.6 million in Q1 2022.
• The 5-year median for Enterprise Value is -$18.0 million (2023), against an average of -$19.3 million.
• Across the five-year window, Enterprise Value jumped 68.45% in 2025 and sank 89.89% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$18.6 million in 2022, then sank by 38.02% to -$25.7 million in 2023, then soared by 41.08% to -$15.1 million in 2024, then dropped by 17.2% to -$17.7 million in 2025, then grew by 20.37% to -$14.1 million in 2026.
• Per Business Quant, the three latest GALT Enterprise Value figures stand at -$14.1 million (Q1 2026), -$17.7 million (Q4 2025), and -$11.5 million (Q3 2025).